Gilead has submitted a supplemental new drug application (sNDA) to the US Food and Drug Administration (FDA) for antiviral Descovy (emtricitabine and tenofovir alafenamide) for pre-exposure prophylaxis (PrEP) to reduce...
5 April 2019 News
1 April 2019 News
AstraZeneca has announced the US Food and Drug Administration (FDA) has granted selumetinib, a MEK 1/2 inhibitor co-commercialised with Merck, breakthrough therapy designation.
29 March 2019 News
Gilead Sciences and Galapagos NV have announced their drug filgotinib met its primary endpoint in week 24 of two Phase III trials, FINCH 1 and FINDCH 3, of rheumatoid arthritis...
28 March 2019 Comment
Throughout the three-year partnership, Celgene plans to use the AI technology to accelerate the discovery of small therapeutic drug candidates for three programmes in oncology and autoimmunity.
26 March 2019 News
North American pharma company CytoDyn has announced that its primary product leronlimab exceeded expectations as a monotherapy for human immunodeficiency virus (HIV).
21 March 2019 AI
Oxford-based artificial intelligence (AI) drug discovery company Exscientia has announced it has entered into three-year partnership with Celgene for an initial upfront payment of $25m.
21 March 2019 News
The European Medicines Agency has advised patients and clinicians to not exceed the 5mg twice daily recommendation dose of Pfizer’s Xeljanz (tofacitinib) for rheumatoid arthritis.
19 March 2019 Comment
Pfizer seemed unmoved by the safety alert issued by the FDA and positioned Xeljanz as the first and only JAK inhibitor approved for moderate to severe ulcerative colitis.
8 March 2019 News
Johnson & Johnson’s subsidiary Janssen Pharmaceuticals and ViiV Healthcare have revealed 48 week data from two pivotal Phase III trials showing injections of their long-acting, monthly combination of cabotegravir and...